The powerhouse of the cell
Driving a new means of fighting disease
Overview of our Patent-Pending MOT™ Technology
While conducting cancer research in the U.S., the benefits of mitochondria transplantation were discovered and exclusively licensed to MitoSense, under the name Mitochondria Organelle Transplantation (MOT™). During the past two years, MOT™ has shown tremendous promise in early research and testing. This early evidence indicates MOT™ may alleviate some symptoms associated with neurodegenerative disorders such as ALS, Alzheimer’s, Parkinson’s, and others. Further research and testing are under way.
There is currently no other therapy available like MOT™ and the early indications point to much broader applications, that could benefit millions of Americans suffering from various neurodegenerative issues and diseases.
Watch the promise of Mitochondria Organelle Transplantation (MOT™) to fight neurodegenerative diseases.
Applications
Validating Science
-
MitoSense's Baucom and Jiang have also conducted research on how MOT™ technology can be a potential therapeutic for mitochondria dysfunction in patients suffering from severe cases of COVID-19.
-
NASA research has identified mitochondrial health as a crucial component to the future of space travel
-
Mayo Clinic research in 2012 discovered that mitochondrial dysfunction is present early in Alzheimer's disease before memory loss.
-
Recent Mayo Clinic research has targeted mitochondria as a means of treating Alzheimer's disease.
-
Additional Alzheimer's research has shown that boosting mitochondrial health in mice reduced the number of amyloid plaques, thus resulting in improved cognitive function.
Path Forward
We are actively forming partnerships with various public and private institutions to expand our research and reach, so we can help improve as many lives as possible.